[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563259":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":66,"collaborators":20,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":20,"enrollmentInfo":79,"targetDuration":20,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Imaging Cohort","EXPERIMENTAL","Up to 15 subjects will enroll in this imaging study at the University of Pennsylvania. Those with a diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist OR New contrast-enhancing lesion or lesions showing increased enhancement (\\>25% increase) in a patient with a historical diagnosis of glioblastoma.",[13],"Drug: Fluciclovine F18",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Fluciclovine F18","To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \\[18F\\]Fluciclovine and 18F-FDG PET.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Ali Nabavizadeh, MD","University of Pensylvania","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Leeanne Lezotte","CONTACT","8563643137","leeanne.lezotte@pennmedicine.upenn.edu",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Jeremy T Westerman, B.S.","2159199110","jeremy.westerman@pennmedicine.upenn.edu",[37,57],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Hospital of the University of Pennsylvania","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-75.16362,39.95238,{"lat":49,"lon":48},[52,55,56],{"name":53,"role":29,"phone":34,"phoneExt":20,"email":54},"Jeremy T Westerman, B.S. Biology","Jeremy.Westerman@pennmedicine.upenn.edu",{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"facility":58,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"University of Pennsylvania",{"type":46,"coordinates":60},[48,49],{"lat":49,"lon":48},[63,64,65],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":58,"oldNameTitle":20,"oldOrganization":20},"Ali Nabavizadeh","Principal Investigator","100563259","early-phase-1-multitracer-18ffluciclovine-and-18f-fdg-pet-and-advanced-mri-for-metabolic-profiling-of-glioblastoma-100563259",false,"NCT06613841","Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma","Pilot Study to Evaluate Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI Methods at 7Tesla Metabolic Profiling of Glioblastoma","GBM","Inclusion Criteria:\n\n* Participants will be ≥ 18 years of age\n\nMust meet the following criteria:\n\n-Diagnosis of a new intra-axial brain mass that is consistent with GBM per the opinion of a Penn neuroradiologist.\n\nOR\n\n* New contrast-enhancing lesion or lesions showing increased enhancement (\\>25%increase) in a patient with a historical diagnosis of glioblastoma (histologic or molecular proof) on standard MRI after completion of treatment\n* Recommended for clinically indicated surgical resection\n* Life expectancy of greater than 3 months in the opinion of an investigator or treating physician.\n* Karnofsky performance status ≥ 60 per medical record review\n* Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n* Females who are pregnant or breastfeeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential prior to injection.\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study\n* Contraindications to MRI\n* Only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study","ALL","18 Years",{"count":80,"type":81},15,"ESTIMATED","INTERVENTIONAL",[84],"EARLY_PHASE1","* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \\[18F\\]Fluciclovine and 18F-FDG PET.\n* To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine\u002Fglutamate, glucose, and lactate metabolism.\n* To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla",[87,88,89],"Glioblastoma","Recurrent Glioblastoma","Glioblastoma Multiforme of Brain",[91,92,87],"Early Phase 1","Cohort","2025-11-24",{"date":95,"type":96},"2025-11-28","ACTUAL",{"date":98,"type":96},"2025-05-01",{"date":100,"type":81},"2026-12-31",{"name":5,"class":6},2]